Nucresiran
ALN-TTRSC04-004
Phase 3 small_molecule active
Quick answer
Nucresiran for Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy is a Phase 3 program (small_molecule) at ALNYLAM PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ALNYLAM PHARMACEUTICALS, INC.
- Indication
- Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active